This content has been archived. It may no longer be relevant
Introduction
Robert F. Kennedy Jr. being picked by President-elect Trump to head of the Department of Health & Human Services hit the 6 stocks in the MunAiMarkets Ai-focused micro/small-cap clinical-stage drug discovery stocks portfolio hard last week with NO constituents advancing. Below are the details:
AI-Focused Drug Discovery Stocks Portfolio: DOWN 9.6% w/e November 15th
- +/- 10%:
- <10-15%:
- Recursion Pharmaceuticals (RXRX): – 13.0%
- Exscientia (EXAI): -13.8%
- <15-20%:
- < 20%:
Summary
The MunAiMarkets Ai-focused micro/small-cap clinical-stage drug discovery stocks portfolio went DOWN 9.6% w/e November 15th and is now DOWN 45.2% YTD.